Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Cagrilintide for Sale > CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1
CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1 buy - large image1
CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1 buy - image1
CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1 buy - image2
CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1 buy - image3
CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1 buy - image4
CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1 buy - image5
CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1 buy - image6

CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1

TDS 66 Inquiries

Unit Price:

$50/BOU FOB

Get Latest Price
CAS No.:

1415456-99-3

Grade:

Research Grade

Content:

99%

Port:

深圳

Brand:

Generic

Packaging:

5mg/Vial

Price valid (until):

2026-10-16

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,100% TT in advance
Average Lead Time:
1 days
Qualification:
Main Products:

Peptides

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Name:Elare

    Whatsapp:+852 5535 7215

    Please add me for our latest price list and COA


      Product Detail  



    CGL5 5mg Product Details

    Product Overview

    Product Name: CGL5
    Specification: 5 mg
    Product Code: CGL5
    Packaging: Subject to the actual product packaging and verified supplier documentation
    Product Form: Subject to the actual product and applicable product documentation

    CGL5 5mg is a product identified by the product name, product code, and specification stated above. This product description is intended to provide accurate product identification and general purchasing information.

    All information included in this listing should accurately correspond to the actual product offered by the supplier. Product identity, specification, packaging, technical characteristics, quality information, safety information, and regulatory status should be verified against authentic and current documentation before publication or commercial transaction.

    Where a particular parameter has not been verified, it should not be presented as a confirmed product characteristic. The supplier should update the product information whenever the actual product, documentation, packaging, or applicable regulatory requirements change.

    Product Specification

    The stated specification of this product is 5 mg.

    The actual package configuration, quantity, batch information, appearance, physical characteristics, purity, assay, and other quality parameters should be determined according to the relevant product documentation.

    The product code “CGL5” should not be used to infer chemical composition, regulatory classification, safety status, intended application, or other technical characteristics that have not been officially verified.

    Where batch-specific documentation is available, the applicable batch documentation should prevail over general marketplace information.

    Customers requiring detailed technical information should request the relevant documentation from the supplier before placing an order.

    Product Identification

    For accurate product identification, the supplier should maintain complete and consistent product information.

    Depending on the actual product, relevant information may include:

    • Product name;
    • Product code;
    • Product specification;
    • Manufacturer information;
    • Batch or lot information;
    • Packaging information;
    • Technical specifications;
    • Quality documentation;
    • Safety documentation, where applicable;
    • Regulatory documentation, where applicable.

    If a CAS number is applicable to the actual product, it should only be published after verification through reliable and relevant documentation.

    Molecular formula, molecular weight, purity, assay, composition, hazard classification, transportation classification, and other technical parameters should likewise only be published when supported by appropriate documentation.

    Unverified information should not be invented, estimated, or copied from another product.

    Quality Information

    The supplier should maintain appropriate quality records for CGL5 5mg.

    Depending on the actual product and applicable requirements, supporting documentation may include a product specification sheet, Certificate of Analysis, batch documentation, manufacturer documentation, Safety Data Sheet, or other legally permitted documents.

    Quality information should correspond to the actual product and, where applicable, the relevant production batch.

    Documents belonging to another product, another manufacturer, or another batch should not be submitted as supporting evidence for CGL5.

    Customers may request relevant quality documentation before purchase where detailed verification is required.

    Regulatory Compliance

    The publication and transaction of CGL5 5mg are subject to current ECHEMI requirements and all applicable laws and regulations.

    The regulatory classification of a product should be determined according to its actual identity, composition, properties, intended application, and applicable jurisdiction.

    If the actual product falls within a regulated category, including hazardous chemicals, dangerous goods, controlled substances, restricted products, pharmaceutical products, or other specially regulated categories, the supplier must comply with the applicable requirements before publication, sale, shipment, importation, or other commercial activity, as applicable.

    Where a specific license, permit, registration, supplier qualification, authorization, or other regulatory document is required, the supplier should obtain and maintain the relevant documentation.

    The product should only be published and supplied within the permitted scope of the supplier's qualifications.

    ECHEMI Platform Compliance

    The supplier should submit truthful, accurate, complete, and consistent product information for ECHEMI review.

    The supplier should not attempt to bypass platform review by changing the actual product name, using an unrelated CAS number, splitting keywords, concealing the actual identity of the product, changing the product category without factual basis, or making unsupported statements concerning regulatory status.

    The product title, product description, specification, images, supporting documents, packaging information, and actual goods should remain consistent.

    If ECHEMI requests additional qualification documents or supporting materials, the supplier should provide authentic documents through the appropriate platform process.

    This product description does not state that CGL5 is hazardous or non-hazardous, regulated or non-regulated, restricted or unrestricted.

    The actual regulatory status should be determined from verified documentation and applicable laws and regulations.

    Safety Information

    Safety information should be based on the actual product and valid supporting documentation.

    Where a Safety Data Sheet or equivalent safety document is applicable, customers should review the relevant information before handling, storing, transporting, or otherwise dealing with the product.

    Specific hazard statements, precautionary statements, hazard classifications, emergency procedures, transportation classifications, or packaging groups should not be stated unless supported by appropriate documentation.

    The absence of a particular safety statement in this general product description should not be interpreted as confirmation that the product has no safety or regulatory requirements.

    Storage and Handling

    Storage and handling requirements should be determined according to official documentation applicable to the actual product.

    Customers should follow the instructions provided on the actual product label and relevant technical or safety documentation.

    Specific storage temperatures, environmental conditions, shelf-life information, or handling procedures should only be published when supported by reliable product documentation.

    The supplier should ensure that the product is packaged, stored, and handled in accordance with applicable requirements.

    Packaging Information

    The final packaging configuration should be confirmed against the actual product.

    Packaging information may include container type, quantity, labeling, batch identification, product identification, and other applicable markings.

    Product images used on the platform should accurately represent the actual goods.

    Images and descriptions should not imply certification, authorization, safety classification, product composition, or regulatory status that cannot be supported by official documentation.

    Where special packaging or labeling requirements apply, the supplier should ensure compliance before shipment.

    Transportation

    Transportation requirements depend on the actual characteristics and regulatory classification of the product.

    Before shipment, the supplier and relevant logistics provider should determine whether special transportation requirements apply.

    No specific dangerous-goods classification, transportation category, or regulatory exemption should be stated without appropriate supporting documentation.

    If the actual product is subject to regulated transportation requirements, the applicable packaging, labeling, documentation, carrier, and handling procedures should be followed.

    For international transactions, the parties should verify applicable import, export, customs, transportation, and documentation requirements in the destination market.

    Intended Application

    Any statement regarding the intended application of CGL5 should be based on verified product information and applicable documentation.

    This listing does not make unsupported claims concerning medical treatment, therapeutic effects, diagnosis, disease prevention, performance enhancement, or other specialized effects.

    Where a legitimate professional or industrial application is supported by official documentation, it should be described accurately and only within the scope permitted by applicable laws, regulations, and ECHEMI requirements.

    No unsupported claim of approval, authorization, certification, efficacy, or official recognition should be included.

    Documentation

    Customers may request applicable product documentation before placing an order.

    Depending on the actual product, relevant documents may include:

    • Product specification information;
    • Certificate of Analysis, where applicable;
    • Safety Data Sheet, where applicable;
    • Batch or lot information;
    • Manufacturer documentation;
    • Packaging information;
    • Regulatory documentation, where applicable;
    • Supplier qualification documents, where applicable.

    All documents should be authentic, current, relevant, and traceable to the actual product.

    If ECHEMI requires a particular document or qualification, the supplier should provide the appropriate documentation through the required process.

    Customer Responsibilities

    Customers should determine whether purchasing, importing, possessing, storing, handling, transporting, or using CGL5 is permitted under the laws and regulations applicable to their location and intended application.

    Where an import license, registration, permit, end-use document, authorization, or other qualification is required, the customer should complete the applicable procedures before purchasing or importing the product.

    Customers should review relevant product documentation and safety information before making a purchasing decision.

    Supplier Responsibilities

    The supplier is responsible for ensuring that all information submitted to ECHEMI accurately represents the actual product.

    The supplier should ensure that:

    • The product identity is accurate;
    • The stated specification is correct;
    • Technical parameters are supported by documentation;
    • Product images represent the actual goods;
    • Uploaded documents correspond to the listed product;
    • Batch information is accurate where applicable;
    • Required qualifications are valid;
    • Applicable regulatory requirements are satisfied;
    • No misleading or unsupported claims are included.

    Where a particular product category requires qualification documents, the supplier should complete the applicable qualification process before publication or transaction.

    Information Verification Before Publication

    Before submitting CGL5 5mg for platform review, the supplier should verify the following information:

    Product Name: CGL5
    Specification: 5 mg
    Product Code: CGL5
    CAS Number: To be confirmed from authentic documentation, if applicable
    Molecular Formula: To be confirmed, if applicable
    Molecular Weight: To be confirmed, if applicable
    Purity/Assay: To be confirmed from applicable quality documentation
    Manufacturer: To be confirmed
    Packaging: To be confirmed
    Safety Classification: To be determined according to applicable documentation and regulations
    Transportation Classification: To be determined where applicable
    Supplier Qualification: To be confirmed where required

    If any item has not been verified, it should remain unconfirmed rather than being completed with assumptions.

    Compliance Disclaimer

    This product description is provided for general product identification and purchasing information purposes only.

    It does not constitute a certification that CGL5 5mg is non-hazardous, non-regulated, unrestricted, approved, authorized, or exempt from any applicable regulatory requirement.

    The actual regulatory status of CGL5 5mg must be determined according to the authentic product identity, official product documentation, applicable laws and regulations, and current ECHEMI requirements.

    If the product is subject to hazardous-chemical controls, restricted publication, qualification requirements, or other regulatory controls, the supplier should complete the applicable compliance procedures before publication or transaction.

    Nothing in this description is intended to circumvent ECHEMI review, qualification requirements, or applicable laws and regulations.

    Final Notice

    The supplier should review the complete product information and supporting documentation before submitting CGL5 5mg for platform approval.

    If ECHEMI identifies the product or its description as potentially falling within a regulated category, the supplier should verify the actual product identity and regulatory status rather than attempting to conceal, rename, or otherwise alter relevant information.

    Where qualification documents are required but have not yet been uploaded or verified, the supplier should complete the applicable documentation process before making claims that depend on such qualifications.

    All product information should be authentic, accurate, current, complete, and consistent with the actual goods.

    In the event of any conflict between this general product description, official product documentation, applicable laws and regulations, or ECHEMI platform requirements, the applicable official requirements and verified documentation shall prevail.





    Items Specifications
    Product Name CGL5
    Grade Research Grade
    Package 5mg/Vial
    Appearance White Lyophilized Powder
    Model CGL5 5mg
    Brand Generic

    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 1

    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 2
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 3
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 4
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 5
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 6
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 7
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 8
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 9
    Shop Retatrutide 15mg High Purity Peptide Research Compound Powder Product-Detailed Image 10
    ECHEMI Editorial Reference

    Cagrilintide is a long-acting amylin analog and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Cagrilintide is characterized by its peptide structure and amylin receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.

    Certificates
    • CGL5 High-quality peptides,white powder,provide home delivery service-available in stock in the warehouse 1 Certificates 1 TDS

    Basic Info
    Product Name:

    Cagrilintide

    Other Name:

    ‌Cagrilitide、Cagrilintide acetate、Caglitide、Kagliptin、Cargliptin、Cargilinitide

    CAS No.:

    1415456-99-3

    Molecular Formula:

    C194H312N54O59S2

    Molecular Weight:

    0

    EC Number:

    206-141-6

    Color/Form:

    White to off-white

    Research
    Class:

    Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)

    Status:

    Investigational — Phase 3 (REDEFINE program, CagriSema combination)

    Mechanism:

    A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity.

    Activity note:

    Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.

    Source:

    MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.

    Clinical Development:

    NCT05249895; NCT05249882

    References
    PubChem:

    PubChem

    Disclaimer:

    Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptides

    Location:

    Y17, Room 310, East Third Floor, No. 64 and 66 Jianzhong Road, Tianhe District, Guangzhou City

    Payment Terms:

    TT against copy of documents,100% TT in advance

    Average lead Time:

    1 days

    Total Employees:

    11-50

    Year of Establishment:

    2026

    Founded in 2024, PGpeptides is a specialized supplier of high-purity
    research peptides serving the global scientific community. With deep
    industry expertise, we deliver consistent product quality, competitive
    pricing, and flexible service tailored to research institutions, laboratories,
    and distributors worldwide.
    Our operations span North America, Europe, Asia, Australia, and the
    Middle East, backed by a mature international trade infrastructure and a
    reliable global fulfillment network. We have earned strong recognition 
    and trust across the markets we serve.
  • Inquiry History
    66 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Cagrilintide

    20 MG Sep 30, 2026
    Australia

    Cagrilintide

    20 MG Aug 17, 2026
    United Kingdom

    Cagrilintide

    10 MG Jul 31, 2026
    France

    Cagrilintide

    10 MG May 22, 2026
    Australia

    Cagrilintide

    4 MT Mar 9, 2026
    United States

    Cagrilintide

    15 MG Feb 25, 2026
    United States

    Cagrilintide

    10 PCS Dec 27, 2025
    United States

    Cagrilintide

    2 MT Dec 21, 2025
    United States

    Cagrilintide

    100 MG Oct 28, 2025
    United States

    cagrilintide

    2 MT Aug 8, 2025
    Philippines

    Retatrutide

    5 MG Aug 5, 2025
    China

    Cagrilintide

    100 G May 6, 2025
    United States

    cagrilintide

    5 MG Feb 18, 2025
    United States

    Cagrilintide

    3 MT Feb 7, 2025
    United States

    Cagrilintide

    100  Nov 12, 2024
    United States

    Cagrillintide Lyophilized powder

    100 MG Jul 4, 2024
    United States

    Cagrillintide Lyophilized powder

    1000 MG Apr 20, 2024
    United States

    Cagrilintide

    10 MG Sep 23, 2026
    United States

    Cagrilintide

    25 MG Aug 31, 2026
    United States

    Cagrlintide

    1 MT Jul 31, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.